Intramuscular injection of soluble receptor for advanced glycation endproducts expression vector prevents the development of streptozotocin-induced diabetes mellitus in rats on high fat diet

Journal of Diabetes

Volumn 3, Issue 4, 2011, Pages 309-316

  Su, Xudong ^a,b   Meng, Xiuxiang ^a   Sun, Changkai ^a   Liu, Liping ^a,c   Su, Benli ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b LIAOCHENG PEOPLE'S HOSPITAL   (China)

^c Dandong Second People's Hospital   (China)

Author keywords

Advanced glycation endproducts; Diabetes mellitus; High fat diet; Soluble receptor

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MALONALDEHYDE; PLASMID VECTOR; STREPTOZOCIN; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; EXPRESSION VECTOR; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; LIPID DIET; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; GENETIC VECTORS; GLYCOSYLATION END PRODUCTS, ADVANCED; INJECTIONS, INTRAMUSCULAR; MALE; MALONDIALDEHYDE; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN;

EID: 82355169223     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/j.1753-0407.2011.00153.x     Document Type: Article

References (36)

1. Fox CS, Larson MG, Leip EP, Meigs JB, Wilson PW, Levy D. Glycemic status and development of kidney disease: The Framingham Heart Study. Diabetes Care. 2005; 28: 2436-40.
2. Cappellari A, Airaghi L, Capra R et al. Early peripheral nerve abnormalities in impaired glucose tolerance. Electromyogr Clin Neurophysiol. 2005; 45: 241-4.
3. Haslbeck KM, Schleicher E, Bierhaus A et al. The AGE/RAGE/NF-(kappa)B pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT). Exp Clin Endocrinol Diabetes. 2005; 113: 288-91.
4. Singleton JR, Smith AG, Russell JW, Feldman EL. Microvascular complications of impaired glucose tolerance. Diabetes. 2003; 52: 2867-73.
5. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med. 2007; 24: 137-44.
6. Vlassara H, Striker G. Glycotoxins in the diet promote diabetes and diabetic complications. Curr Diab Rep. 2007; 7: 235-41.
7. Negrean M, Stirban A, Stratmann B et al. Effects of low- and high-advanced glycation endproducts meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr. 2007; 85: 1236-43.
8. Uribarri J, Cai W, Peppa M et al. Circulating glycotoxins and dietary advanced glycation endproducts: Two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci. 2007; 62: 427-33.
9. Koschinsky T, He CJ, Mitsuhashi T et al. Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA. 1997; 94: 6474-9.
10. Genuth S, Sun W, Cleary P et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes. 2005; 54: 3103-11.
11. Monnier VM, Bautista O, Kenny D et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: Relevance of glycated collagen products versus HbA1c as markers of diabetic complications. Diabetes. 1999; 48: 870-80.
12. Hofmann SM, Dong H-J, Li Z et al. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes. 2002; 51: 2082-9.
13. Sandu O, Song K, Cai W, Zheng F, Uribarri J, Vlassara H. Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake. Diabetes. 2005; 54: 2314-9.
14. Chen Y, Yan S, Colgan J et al. Blockade of Late Stages of Autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J Immunol. 2004; 173: 1399-405.
15. Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta. 2000; 1498: 99-111.
16. Katakmi N, Matsuhisa M, Kaneta H et al. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: Its possible association with diabetic vascular complications. Diabetes Care. 2005; 28: 2716-21.
17. Flyvbjerg A, Denner L, Schrijvers BF et al. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes. 2004; 53: 166-72.
18. Bucciarelli LG, Wendt T, Qu W et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation. 2002; 106: 2827-35.
19. Saisho Y, Komiya N, Hirose H. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: Blood pressure-independent effect of valsartan. Diabetes Res Clin Pract. 2006; 74: 201-3.
20. Jinnouchi Y, Yamagishi S, Takeuchi M et al. Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin Exp Med. 2006; 6: 191-3.
21. Yamagishi S, Nakamura K, Matsui T, Inoue H. A novel pleiotropic effect of atorvastatin on advanced glycation end product (AGE)-related disorders. Med Hypotheses. 2007; 69: 338-40.
22. Forbes JM, Thorpe SR, Thallas-Bonke V et al. Modulation of soluble receptor for advanced glycation endproducts by angiotensin-converting enzyme-1i inhibition in diabetic nephropathy. J Am Soc Nephrol. 2005; 16: 2363-72.
23. Reed MJ, Meszaros K, Entes LJ et al. A new rat model of type 2 diabetes: The fat-fed, streptozotocin-treated rat. Metabolism. 2000; 49: 1390-4.
24. Islam MS, Choi H. Nongenetic model of type 2 diabetes: A comparative study. Pharmacology. 2007; 79: 243-9.
25. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: A model for type 2 diabetes and pharmacological screening. Pharmacol Res. 2005; 52: 313-20.
26. Zhang F, Ye C, Li G et al. The rat model of type 2 diabetic mellitus and its glycometabolism characters. Exp Anim. 2003; 52: 401-7.
27. Zhao BZ, Bai XP. An experimental rat model of type 2 diabetes mellitus [Chinese]. Zhongguo yaowu yu linchuang 2002; 6: 383-5.
28. Goldberg T, Cai W, Peppa M et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc. 2004; 104: 1287-91.
29. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation. 2006; 114: 597-605.
30. Parveen K, Khan MR, Mujeeb M, Siddiqui WA. Protective effects of Pycnogenol on hyperglycemia-induced oxidative damage in the liver of type 2 diabetic rats. Chem Biol Interac. 2010; 186: 219-27.
31. Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: From disease marker to potential therapeutic target. Curr Med Chem. 2006; 13: 1971-8.
32. Unoki H, Yamagishi S. Advanced glycation end products and insulin resistance. Curr Pharm Des. 2008; 14: 987-9.
33. Zhang Z, Liew CW, Handy DE et al. High glucose inhibits glucose-6-phosphate dehydrogenase, leading to increased oxidative stress and β-cell apoptosis. FASEB J. 2009; 24: 1497-505.
34. Lo MC, Lu CI, Chen MH, Chen CD, Lee HM, Kao SH. Glycoxidative stress-induced mitophagy modulates mitochondrial fates. Ann N Y Acad Sci. 2010; 1201: 1-7.
35. Lee BW, Chae HY, Kwon SJ, Park SY, Ihm J, Ihm SH. RAGE ligands induce apoptotic cell death ofpancreaticβ-cells via oxidative stress. Int J Mol Med. 2010; 26: 813-8.
36. Zhu Y, Shu T, Lin Y et al. Inhibition of the receptor for advanced glycation endproducts (RAGE) protects pancreatic β-cells. Biochem Biophys Res Commun. 2011; 404: 159-65.